Summary
Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts
Ocugen NASDAQ: OCGN is positioning its ophthalmology gene therapy portfolio around treatments for inherited retinal diseases and dry age-related macular degeneration, with pivotal-stage programs in retinitis pigmentosa, Stargardt disease and geographic atrophy, Chairman, CEO and Co-Founder Shankar Musunuri said during a Canaccord discussion.
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls
OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.
Ocugen Q2 Earnings Call Highlights
Ocugen NASDAQ: OCGN said its second quarter marked progress across its late-stage ophthalmology pipeline, including FDA clearance to begin a Phase III study of OCU410 in geographic atrophy and an RMAT designation for the program.
Ocugen Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 6,712 | $5,556.8 | $9,195.44 | $3,638.64 | 65.48% |
| NA Nizar Araji National Bank Of Canada /FI/ | 119,375 | $315,862.23 | $156,381.25 | -$159,480.98 | -50.49% |
| BG Bart Gancher Intech Investment Management LLC | 60,826 | $93,063.78 | $79,682.06 | -$13,381.72 | -14.38% |
| OZI Omar Z. Idilby GMT CAPITAL Corp. | 3.51M | $6.34M | $4.73M | -$1.61M | -25.41% |
 Point72 Asset Management LP Point72 Asset Management LP | 477,821 | $832,829.09 | $645,058.35 | -$187,770.74 | -22.55% |
Ocugen Inc. (OCGN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ocugen Inc. ever had a stock split?
Ocugen Inc. Profile
| Biotechnology Industry | Healthcare Sector | Shankar Musunuri CEO | NASDAQ (CM) Exchange | 67577C105 CUSIP |
| US Country | 116 Employees | 30 Sep 2019 Last Dividend | 30 Sep 2019 Last Split | 3 Dec 2014 IPO Date |
Overview
Ocugen, Inc. is a forward-focused clinical-stage biopharmaceutical company dedicated to pioneering the development of gene therapies aimed at eradicating blindness diseases. With its headquarters nestled in Malvern, Pennsylvania, the company is at the forefront of utilizing breakthrough technologies to create solutions for a range of inherited retinal diseases that to date have had limited treatment options. Ocugen's commitment to innovation extends beyond its therapeutic developments; it supports its ambitious goals through strategic partnerships with entities like CanSino Biologics Inc., emphasizing gene therapy co-development and manufacturing, as well as Bharat Biotech, which bolsters its commercialization strategies, notably with COVAXIN in the United States market.
Products and Services
- OCU400
OCU400 represents a significant breakthrough in the field of gene therapy, serving as a novel product candidate designed to restore retinal integrity and functionality. This innovative approach is unique in its capacity to address a broad spectrum of genetically diverse inherited retinal diseases, including retinitis pigmentosa and leber congenital amaurosis. The ambition behind OCU400 is to provide a versatile treatment option that could benefit patients suffering from various forms of retinal degeneration.
- OCU410 and OCU410ST
Targeting the prevalent condition of dry age-related macular degeneration (AMD), OCU410 and OCU410ST are at the forefront of Ocugen's pipeline, embodying the company's dedication to combatting age-related vision loss. Through cutting-edge research and development, these product candidates aspire to not only address but also ameliorate the effects of AMD, thereby improving the quality of life for those affected by this degenerative condition.
- OCU200
As a testament to Ocugen's innovative spirit, OCU200 is a novel fusion protein currently in the preclinical development stage. It stands as a potential groundbreaking treatment for diabetic macular edema, diabetic retinopathy, and wet AMD. By targeting these significant causes of blindness, OCU200 showcases the company's commitment to developing treatments that address the underlying causes of vision loss with the potential to profoundly impact patients' lives.
